Meryem EL AZZOUZI

Dr. Meryem EL AZZOUZI


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
MAMeryem EL AZZOUZI
Meryem EL AZZOUZI
HEH E
H E
CAChaimae Hafidi Alaoui
Chaimae Hafidi Alaoui
ICImane Chaoui
Imane Chaoui
LBLaila Benbacer
Laila Benbacer
MMMohammed EL MZIBRI
Mohammed EL MZIBRI
Vascular endothelial growth factor (VEGF) and its receptors (VEGFR1 and VEGFR2) are the most important tissue factors involved in tumor growth and angiogenesis. The aim of this study was to evaluate the promoter mutational status of VEGFA and the expression levels of VEGFA, VEGFR1, and VEGFR2 in bladder cancer (BC) tissues and to correlate the results with the clinical–pathological parameters of BC patients. A total of 70 BC patients were recruited at the Urology Department of the Mohammed V Military Training Hospital in Rabat, Morocco. Sanger sequencing was performed to investigate the mutational status of VEGFA, and RT-QPCR was used to evaluate the expression levels of VEGFA, VEGFR1, and VEGFR2. Sequencing of the VEGFA gene promoter revealed the presence of −460T/C, −2578C/A, and −2549I/D polymorphisms, and statistical analyses showed a significant correlation between −460T/C SNP and smoking (p = 0.02). VEGFA and VEGFR2 expressions were significantly up-regulated in patients with NMIBC (p = 0.003) and MIBC (p = 0.03), respectively. Kaplan–Meier analyses showed that patients with high VEGFA expression had significantly longer disease-free survival (p = 0.014) and overall survival (p = 0.009). This study was very informative, showing the implication of VEGF alterations in BC, suggesting that VEGFA and VEGFR2 expressions could be promising biomarkers for the better management of BC.

21 January 2025 in Cancer Genetics
Verified
Journal Article
Closed access
MAMeryem EL Azzouzi
Meryem EL Azzouzi
BABOUTAINA ADDOUM
BOUTAINA ADDOUM
HAHajar El Ahanidi
Hajar El Ahanidi
IHIlias Hassan
Ilias Hassan
MTMohammed Tetou
Mohammed Tetou
ICImane Chaoui
Imane Chaoui

31 January 2022 in Annals of Cancer Research and Therapy
Verified
Journal Article
Open access
PDF file
CAChaimae Hafidi Alaoui
Chaimae Hafidi Alaoui
HAHajar El Ahanidi
Hajar El Ahanidi
MAMeryem EL AZZOUZI
Meryem EL AZZOUZI
AFAbdelkarim Filali-Maltouf
Abdelkarim Filali-Maltouf
ICImane Chaoui
Imane Chaoui
MMMohammed EL MZIBRI
Mohammed EL MZIBRI
Background: Human telomerase reverse transcriptase (hTERT) promoter mutations are common genetic events in bladder cancer (BC) and have been recognized as potential biomarkers for BC diagnosis and prognosis. Detection of TERT promoter mutations as urine-based tests has previously been reported to detect primary and recurrent BC. This study was planned to evaluate hTERT promoter mutations in both biopsies and urines from BC patients to assess the interest and the usefulness of introducing these biomarkers for better management of BC in Morocco. Methods: In a cohort study involving a series of BC 70 patients with different stages and grades, hTERT promoter mutations were identified in both fresh biopsies and urine sediments by PCR amplification and DNA sequencing. Results: Overall, hTERT promoter mutations were reported in 60% of cancer biopsies (42/70), the hotspot mutations C228T and C250T were respectively identified in 80.95% (34/42) and 16.67% (7/42) of positive cases. Other mutations: A161C and G149T were also reported and were obtained in 2.38% (1/42) and 2.38% (1/42), respectively. hTERT promoter mutations were identified in 30% of matched urine sediments (21/70) and showed an overall sensitivity of 50% and specificity of 100%. In patients with non-muscle invasive bladder cancer, no statistically significant association was detected between TERT promoter mutations and recurrence-free survival (HR: 1.224, 95% CI: 0.373–4.011, p = 0.739), and overall survival (HR: 0.363, 95% CI: 0.041–3.244, p = 0.364). Conclusion: hTERT promoter mutations are early events occurring with high frequencies and can be identified in the exfoliated cells, making them an interesting non-invasive biomarker for diagnosis and follow-up of bladder cancer.